Emergent BioSolutions (EBS) Operating Income (2011 - 2026)
Emergent BioSolutions (EBS) posted quarterly Operating Income of $10.5 million for Q1 2026, down 78.96% year-over-year from $49.9 million in Q1 2025, and up 137.63% quarter-over-quarter from -$27.9 million in Q4 2025.
Emergent BioSolutions (EBS) Operating Income (2011 - 2026) Analysis & Trends
Emergent BioSolutions' Operating Income history runs 16 years deep, the most recent figure standing at $10.5 million for Q1 2026.
- In Q1 2026, Operating Income fell 78.96% year-over-year to $10.5 million; the TTM figure through Mar 2026 stood at $60.7 million (up 161.56% YoY), while the FY2025 annual figure was $100.1 million, up 192.09% from the prior year.
- Operating Income for Q1 2026 stood at $10.5 million, up from -$27.9 million in the prior quarter.
- The five-year high for Operating Income was $76.5 million in Q3 2025, with the low at -$292.9 million in Q2 2023.
- The 5-year median for Operating Income is -$27.9 million (2025), against an average of -$52.6 million.
- The sharpest annual moves came in 2023 and 2024: Operating Income sank 2239.13% in 2023, then soared 126.96% in 2024.
- Emergent BioSolutions' Operating Income stood at -$55.3 million in 2022, then gained by 20.8% to -$43.8 million in 2023, then surged by 78.31% to -$9.5 million in 2024, then tumbled by 193.68% to -$27.9 million in 2025, then jumped by 137.63% to $10.5 million in 2026.
- Business Quant data shows EBS's Operating Income at $10.5 million in Q1 2026, -$27.9 million in Q4 2025, and $76.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Emergent BioSolutions | 248.97 Mn | 108.07 Mn | 137.20 Mn | -125.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -125.10 Mn |
| Mar 31, 2026 | 10.50 Mn |
| Dec 31, 2025 | -27.90 Mn |
| Sep 30, 2025 | 76.50 Mn |
| Jun 30, 2025 | 1.60 Mn |
| Mar 31, 2025 | 49.90 Mn |
| Dec 31, 2024 | -9.50 Mn |
| Sep 30, 2024 | 64.50 Mn |
| Jun 30, 2024 | -203.50 Mn |
| Mar 31, 2024 | 39.80 Mn |
| Dec 31, 2023 | -43.80 Mn |
| Sep 30, 2023 | -242.10 Mn |
| Jun 30, 2023 | -292.90 Mn |
| Mar 31, 2023 | -147.60 Mn |
| Dec 31, 2022 | -55.30 Mn |
| Sep 30, 2022 | -45.30 Mn |
| Jun 30, 2022 | -76.30 Mn |
| Mar 31, 2022 | 6.90 Mn |
| Dec 31, 2021 | 286.80 Mn |
| Sep 30, 2021 | -44.70 Mn |